Your session is about to expire
← Back to Search
Targeted Cancer Drugs for Cancer (CAPTUR Trial)
CAPTUR Trial Summary
This trial will study the effects of targeted cancer drugs on patients with specific gene changes.
CAPTUR Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCAPTUR Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CAPTUR Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can take care of myself and am up and about more than half of the day.I do not have severe side effects from previous cancer treatments, except for manageable nerve pain or corrected thyroid issues.I am not on any cancer treatments except for supportive care or ongoing hormone therapy for prostate cancer.I have not had a stroke or heart attack in the last 3 months.I am an adult with an incurable cancer (not brain cancer) and no life-prolonging treatment options or have refused them.My brain metastases are stable, and I haven't had seizures or major changes in my neurological status for a month.I don't have another cancer that could affect this treatment's safety or results.You do not meet the specific requirements for the medication chosen by your doctor.My heart's pumping ability is below 40%.I do not have serious heart conditions like uncontrolled chest pain or heart failure.You have other health problems that could make it difficult for you to take part in the study, such as ongoing infections, uncontrolled high blood pressure, or serious mental health issues.I have had a serious stomach or intestinal bleed in the last month.
- Group 1: Group 6 - Arm CLOSED
- Group 2: Group 8
- Group 3: Group 3 - Arm CLOSED
- Group 4: Group 4 - Arm CLOSED, no patients recruited
- Group 5: Group 13
- Group 6: Group 2 - Arm CLOSED, no patients recruited
- Group 7: Group 1 - Arm CLOSED, no patients recruited
- Group 8: Group 9 Arm CLOSED
- Group 9: Group 7
- Group 10: Group 10
- Group 11: Group 11 - Arm CLOSED
- Group 12: Group 14
- Group 13: Group 12
- Group 14: Group 5
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people are guinea pigs for this experiment?
"This trial requires 720 individuals that fit the pre-determined inclusion criteria. These patients can be recruited from various hospitals, including The Jewish General Hospital in Montreal, Quebec and London Regional Cancer Program in London, Saskatchewan."
What type of cancer do doctors most often prescribe Nivolumab plus Ipilimumab for?
"Nivolumab in conjunction with Ipilimumab can be used to shrink and manage thyroid cancers, metastatic basal cell carcinoma (bcc), as well as malignant neoplasms."
How many different locations are conducting this trial?
"There are 9 different clinical sites running this trial, with locations in Montreal, London and Saskatoon. To limit travel as much as possible, patients should select the nearest location to them when enrolling."
Are we looking for more individuals to participate in this experiment?
"The study is currently looking for new participants, with the date of the clinical trial's posting being October 6th, 2017 and the most recent update on November 14th, 2022."
What are the most severe side effects that have been seen in patients taking Nivolumab and Ipilimumab?
"Nivolumab plus Ipilimumab falls into Phase 2 of clinical trials, meaning that while there is some evidence backing its safety, no such data exists to support efficacy. As a result, our team at Power have given it a score of 2."
Could you please tell me if Nivolumab has been tested in combination with other drugs?
"The first study of nivolumab plus ipilimumab was completed in 1999. Since then, there have been 1995 similar studies published with 1566 currently active. A high concentration of these ongoing trials is based out of the Canadian city Montreal, Quebec."
Share this study with friends
Copy Link
Messenger